Topic: Tysabri
(Reuters) - U.S. regulators have extended their review of Biogen Idec Inc's application to update the prescribing information for its multiple sclerosis drug Tysabri, the company said on Thursday.Biogen, which sells the drug with Irish drugmaker Elan Corp Plc, is seeking to ...
NEW YORK (Reuters) - Four more patients taking Biogen Idec's multiple sclerosis drug Tysabri have developed the serious brain infection known as PML and one of them died, according to the biotechnology company's monthly update.The four new confirmed cases of potentially fatal ...
Irish drugmaker Elan Corp. reported a third-quarter net loss of $43.6 million ((EURO)31.6 million) Wednesday as it paid down debts, cut research and development costs, and focused on increasing sales of drugs that combat multiple sclerosis.. Elan's share of revenue from its ...
BOSTON (Reuters) - Two more patients taking Biogen Idec Inc's multiple sclerosis drug Tysabri have developed a potentially deadly brain infection known as PML, the company said on Wednesday.The Cambridge, Massachusetts-based biotechnology company said in its latest monthly update that as of ...
TYSABRI.After researching the medicine, I found that there were some frightening side-effects. To date, 33 people have developed PML.Tysabri is a comfortable and easy treatment. I am required to have my blood drawn to test my blood counts and liver function because ...
Learn how one amazing woman reveresed her MS symptoms and now leads a completely normal life. Made up of the same amino acids (the major components of proteins) as the interferon beta that is naturally present in the human body, this medication ...
I am both surprised and shocked by the press release surrounding the latest disease modifying drug (DMD) TYSABRI. I am surprised that Biogen, the drug?s manufacturer, is hoping to provide a test capable of alerting a Tysabri user to the potential risk ...
Looks like people at Biogen Idec and Elan Corp., makers of Tysabri, have something to worry about. An article in Dow Jones Newswires states "Deutsche Bank analyst Robyn Karnauskas recently projected that Tysabri's patient discontinuation rate, currently 2% to 3%, will skyrocket ...
Biogen Idec Inc. (BIIB) reported second-quarter earnings per share of $1.27, well above the Zacks Consensus Estimate of $1.08 and the year-earlier figure of 73 cents. Biogen estimates that as of the end of June 2010, about 52,700 patients were on commercial ...
Biogen Idec Inc. said Tuesday its profit more than doubled in the second quarter compared to a year ago, when it entered a partnership on a potential multiple sclerosis drug.. Biogen's share of that revenue increased 17 percent to $219 million. Biogen ...
From Around the Web
Video Gallery
-
Tysabri - How It Works To Fight ...
This is a short 3 minute video that explains how ...2008-07-05 -
Living with Multiple Sclerosis - MS medications - ...
I wanted to talk about my experiences with some MS ...2007-12-23 -
Tysabri Recovery Series - Subscribe to win
I am giving away a signed paperback copy of my ...2012-02-20
